

PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

(aprepitant)

CINVANTI
(aprepitant)

EMEND
(aprepitant)

EMEND INJECTION
(fosaprepitant dimeglumine)

VARUBI
(rolapitant)

Status: CVS Caremark Criteria

Type: Post Limit Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Aprepitant capsules

Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Aprepitant capsules, in combination with other antiemetic agents, are indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Prevention of Postoperative Nausea and Vomiting (PONV)

Aprepitant capsules are indicated in adults for the prevention of postoperative nausea and vomiting.

Limitations of Use

- Aprepitant has not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of aprepitant is not recommended because it has not been studied, and because the drug interaction profile may change during chronic continuous use.

Cinvanti (aprepitant) injectable emulsion

Cinvanti, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single dose regimen.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single dose regimen.
- nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen

Limitations of Use

- Cinvanti has not been studied for the treatment of established nausea and vomiting.

Emend (aprepitant) capsules and oral suspension

Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Emend capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of Emend is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.

Emend (fosaprepitant dimeglumine) for injection

Emend for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.

Varubi (rolapitant) tablets

Varubi is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The request is not for Varubi and the requested drug is being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy
- AND**
- The requested drug will be used in combination with other antiemetic agents

OR

- Aprepitant capsules are being prescribed for the prevention of postoperative nausea and vomiting

Quantity Limits apply.

POST LIMIT QUANTITY

Drug	4 Week Limit*	12 Week Limit*
Cinvanti 130 mg Injection (Single-Dose 130 mg/18 mL Vial)	4 vials (72 mL) / 21 days	Does Not Apply*
Emend 80 mg Capsule	16 capsules / 21 days	Does Not Apply*

Emend 125 mg Capsule	4 capsules / 21 days	Does Not Apply*
Emend 125 mg-80 mg Capsules (Tri-pack contains one 125 mg capsule and two 80 mg capsules)	4 packs (12 capsules) / 21 days	Does Not Apply*
Emend 125 mg Oral Suspension (Single-Dose Kit contains 125 mg / 5 mL)	12 kits / 21 days	Does Not Apply*
Emend 150 mg Injection (Single-Dose 150 mg Vial)	4 vials / 21 days	Does Not Apply*

* The duration of 21 days is used for a 28-day fill period to allow time for refill processing.

* **These drugs are for short-term acute use; therefore, the mail limit will be the same as the retail limit. The intent is for prescriptions of the requested drug to be filled one month at a time, even if filled at mail order; there should be no 3 month supplies filled.**

Drug	Limit*
Aprepitant 40 mg Capsule	6 capsules / 6 months

* **These drugs are for short-term acute use.**

REFERENCES

1. Aprepitant capsules [package insert]. Mahwah, NJ: Glenmark Pharmaceuticals Inc.; January 2020.
2. Cinvanti [package insert]. San Diego, CA: Heron Therapeutics, Inc.; October 2019.
3. Emend capsules and oral suspension [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; October 2020.
4. Emend for injection [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; April 2020.
5. Varubi [package insert]. Deerfield, IL: TerSera Therapeutics LLC; August 2020.
6. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed January 2021.
7. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed January 2021.
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Antiemesis. V.1.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed January 2021.
9. American Society of Clinical Oncology. Understanding Chemotherapy. <https://www.cancer.net/navigating-cancer-care/how-cancer-treated/chemotherapy/understanding-chemotherapy>. May 2019. Accessed January 2021.
10. American Cancer Society. How is Chemotherapy Used to Treat Cancer? <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-is-chemotherapy-used-to-treat-cancer.html>. November 2019. Accessed January 2021.